InMed Pharmaceuticals Inc. (NASDAQ: INM) has unveiled promising preclinical data for its drug candidate INM-901, demonstrating significant potential in addressing neuroinflammation, a key factor in Alzheimer's disease progression. The findings reveal that INM-901 effectively reduces pro-inflammatory cytokines and inflammasome markers, independent of amyloid beta or tau pathology, suggesting a broader application in treating neurodegenerative diseases.
The compound, which is orally administered, targets CB1/CB2 receptors and PPARs, and has shown to improve cognition and behavior in long-term animal studies. This development is crucial as it opens new avenues for Alzheimer's treatment, focusing on neuroinflammation, a less targeted aspect of the disease. InMed Pharmaceuticals plans to proceed with additional preclinical and IND-enabling studies, with Alzheimer's disease as the lead indication.
This breakthrough is significant for the millions affected by Alzheimer's worldwide, offering hope for a treatment that addresses the disease's underlying inflammatory processes. For the pharmaceutical industry, it represents a potential shift towards targeting neuroinflammation in neurodegenerative diseases, expanding the scope of therapeutic strategies beyond amyloid and tau pathologies.
For more information on the preclinical results, visit https://ibn.fm/HBoFJ.
